Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company with no approved products or product revenue, developing two drug candidates. The first, CRB-701, is an antibody-drug conjugate (ADC) that targets Nectin-4 on cancer cells, delivering a toxic payload (MMAE) directly to tumors. CRB-701 is in a Phase 1/2 study across head and neck, cervical, and urothelial cancers, and early data show meaningful tumor response rates alongside a cleaner safety profile — notably lower peripheral neuropathy and skin reactions — than the approved competitor PADCEV. Corbus plans to meet with the FDA in Q1 2026 to discuss registrational trial designs. Corbus licensed CRB-701 from CSPC for the U.S., Canada, EU, UK, and Australia, and owes milestones and royalties on any future sales. The second candidate, CRB-913, is an oral pill for obesity that blocks the CB1 receptor — a mechanism distinct from GLP-1 drugs like Ozempic. CRB-913 is designed to be "peripherally restricted," staying out of the brain to avoid the neuropsychiatric side effects that sank earlier CB1 blockers. Phase 1 data showed early weight loss signals and no serious adverse events or GI side effects. A dose-ranging Phase 1b study began in December 2025, with results expected in summer 2026. CRB-913 is positioned as a standalone obesity treatment or as a combination therapy with GLP-1 drugs. Corbus funds operations through equity and debt issuance and remains years away from any potential approval or commercialization.